Market Cap 221.56M
Revenue (ttm) 138.90M
Net Income (ttm) -107.15M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -77.14%
Debt to Equity Ratio 0.00
Volume 368,500
Avg Vol 675,566
Day's Range N/A - N/A
Shares Out 46.94M
Stochastic %K 6%
Beta 1.05
Analysts Hold
Price Target $7.33

Company Profile

Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all comp...

Industry: Medical Devices
Sector: Healthcare
Phone: 617 301 9400
Address:
Building 1, 900 Middlesex Turnpike, Billerica, United States
SQUEAKSBANDIT
SQUEAKSBANDIT Mar. 9 at 3:29 PM
$QTRX took a handful under 5 if they can execute, the stock doubles plus this year if they sell the company it doubles....
0 · Reply
Swick02
Swick02 Mar. 6 at 6:49 PM
$QTRX loading up here even more, top 5 position now. On a forward basis with $100 mil cash projected at year end and $170 million of revenue at cash flow breakeven, this is trading at .75x enterprise value / revenue at $5…. You’ve got a recovering life sciences market and a new CEO with an impressive background and history or growth. New board members from TMO as well. As the growth picture firms up throughout the year, I think we’ll see QTRX move back towards $10. These business with recurring reagent revenue streams with growth and profitability can trade north of 5x revenue ($20 per share). Now with TMO on the board, a buyout is certainly on the table as well. What better way to get a close look at a business…
1 · Reply
BioGem
BioGem Mar. 4 at 2:13 AM
$QTRX I added to my short . Critical negatives. -Despite a big acquisition last year, the growth rate is low. While operating expenses are accelerating at a faster pace. -Gross margins have plummeted. -Operating and net losses are worse YOY. -Cash burn continues a high clip. I do not believe that mgt will reach cash breakeven anytime soon. -Rev guidance is underwhelming while gross margin will stay under pressure in 2026. -Short interest is increasing. -Analysts price targets are not too optimistic.
0 · Reply
Pika_Capital
Pika_Capital Mar. 2 at 9:56 PM
$QTRX watching closely. New CEO can turn this sinking ship around. Excluding cash it's trading at 1.2x sales
0 · Reply
mikesterz7
mikesterz7 Mar. 2 at 9:48 PM
$QTRX 🚨 🚨 🚨 Revenue of $43.9 million, an increase of 25% compared to $35.2 million in the prior year. GAAP gross margin of 45.7%, as compared to 63.0% in the prior year. Adjusted gross margin (non-GAAP) of 50.0% as compared to 57.7% in the prior year. Adjusted EBITDA (non-GAAP) loss of $7.9 million, compared to a loss of $5.9 million in the prior year. The Company ended the fourth quarter with $121.6 million of cash, cash equivalents, marketable securities, and restricted cash. Adjusted cash usage, after accounting for one-time deal and restructuring costs, was $3.0 million in the fourth quarter. Quanterix is issuing its initial guidance for 2026. The Company expects revenues of $169 to $174 million, GAAP gross margin of 45-49%, and adjusted gross margin (non-GAAP) of 49% to 53%. Quanterix expects to achieve cash flow breakeven performance in the second half of 2026. The Company expects to exit the year with approximately $100 million in cash and no debt.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 2 at 9:39 PM
$QTRX Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.49 down -63.33% YoY • Reported revenue of $43.85M up 24.73% YoY • Quanterix expects to achieve cash flow breakeven in 2026, contingent on meeting revenue and expense objectives, and anticipates 2026 revenue and bookings to be consistent with 2025 results.
0 · Reply
StockNews_Live
StockNews_Live Mar. 2 at 1:33 PM
$QTRX Lucent Diagnostics, a brand of Quanterix Corporation, announced a partnership with Life Line Screening to offer non-invasive blood-based biomarker tests nationally. The partnership aims to expand acce…
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 26 at 4:20 PM
$QTRX Current Stock Price: $6.18 Contracts to trade: $5.0 QTRX Mar 20 2026 Call Entry: $1.00 Exit: $1.42 ROI: 42% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 25 at 3:34 PM
$QTRX RSI: 34.29, MACD: -0.2691 Vol: 0.33, MA20: 6.06, MA50: 6.57 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Feb. 23 at 4:37 PM
$QTRX huge block nearly 700k shares crossed @ 5.60 nearly 1.5% of total shares outstanding
0 · Reply
Latest News on QTRX
Quanterix Corporation (QTRX) Q4 2025 Earnings Call Transcript

Mar 3, 2026, 4:07 AM EST - 12 days ago

Quanterix Corporation (QTRX) Q4 2025 Earnings Call Transcript


Quanterix to Participate in Upcoming Investor Conferences

Feb 26, 2026, 8:33 AM EST - 17 days ago

Quanterix to Participate in Upcoming Investor Conferences


Quanterix Corporation (QTRX) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 7:11 PM EST - 4 months ago

Quanterix Corporation (QTRX) Q3 2025 Earnings Call Transcript


Quanterix Corporation (QTRX) Q2 2025 Earnings Call Transcript

Aug 9, 2025, 2:27 AM EDT - 7 months ago

Quanterix Corporation (QTRX) Q2 2025 Earnings Call Transcript


Quanterix Expands Reach with IVD and Large Reference Labs

Jun 23, 2025, 7:30 AM EDT - 9 months ago

Quanterix Expands Reach with IVD and Large Reference Labs


Quanterix Corporation (QTRX) Q1 2025 Earnings Call Transcript

May 12, 2025, 11:19 PM EDT - 10 months ago

Quanterix Corporation (QTRX) Q1 2025 Earnings Call Transcript


Quanterix Releases Financial Results for the First Quarter of 2025

May 12, 2025, 4:01 PM EDT - 10 months ago

Quanterix Releases Financial Results for the First Quarter of 2025


Quanterix Corporation (QTRX) Q4 2024 Earnings Call Transcript

Mar 17, 2025, 7:19 PM EDT - 1 year ago

Quanterix Corporation (QTRX) Q4 2024 Earnings Call Transcript


SQUEAKSBANDIT
SQUEAKSBANDIT Mar. 9 at 3:29 PM
$QTRX took a handful under 5 if they can execute, the stock doubles plus this year if they sell the company it doubles....
0 · Reply
Swick02
Swick02 Mar. 6 at 6:49 PM
$QTRX loading up here even more, top 5 position now. On a forward basis with $100 mil cash projected at year end and $170 million of revenue at cash flow breakeven, this is trading at .75x enterprise value / revenue at $5…. You’ve got a recovering life sciences market and a new CEO with an impressive background and history or growth. New board members from TMO as well. As the growth picture firms up throughout the year, I think we’ll see QTRX move back towards $10. These business with recurring reagent revenue streams with growth and profitability can trade north of 5x revenue ($20 per share). Now with TMO on the board, a buyout is certainly on the table as well. What better way to get a close look at a business…
1 · Reply
BioGem
BioGem Mar. 4 at 2:13 AM
$QTRX I added to my short . Critical negatives. -Despite a big acquisition last year, the growth rate is low. While operating expenses are accelerating at a faster pace. -Gross margins have plummeted. -Operating and net losses are worse YOY. -Cash burn continues a high clip. I do not believe that mgt will reach cash breakeven anytime soon. -Rev guidance is underwhelming while gross margin will stay under pressure in 2026. -Short interest is increasing. -Analysts price targets are not too optimistic.
0 · Reply
Pika_Capital
Pika_Capital Mar. 2 at 9:56 PM
$QTRX watching closely. New CEO can turn this sinking ship around. Excluding cash it's trading at 1.2x sales
0 · Reply
mikesterz7
mikesterz7 Mar. 2 at 9:48 PM
$QTRX 🚨 🚨 🚨 Revenue of $43.9 million, an increase of 25% compared to $35.2 million in the prior year. GAAP gross margin of 45.7%, as compared to 63.0% in the prior year. Adjusted gross margin (non-GAAP) of 50.0% as compared to 57.7% in the prior year. Adjusted EBITDA (non-GAAP) loss of $7.9 million, compared to a loss of $5.9 million in the prior year. The Company ended the fourth quarter with $121.6 million of cash, cash equivalents, marketable securities, and restricted cash. Adjusted cash usage, after accounting for one-time deal and restructuring costs, was $3.0 million in the fourth quarter. Quanterix is issuing its initial guidance for 2026. The Company expects revenues of $169 to $174 million, GAAP gross margin of 45-49%, and adjusted gross margin (non-GAAP) of 49% to 53%. Quanterix expects to achieve cash flow breakeven performance in the second half of 2026. The Company expects to exit the year with approximately $100 million in cash and no debt.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 2 at 9:39 PM
$QTRX Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.49 down -63.33% YoY • Reported revenue of $43.85M up 24.73% YoY • Quanterix expects to achieve cash flow breakeven in 2026, contingent on meeting revenue and expense objectives, and anticipates 2026 revenue and bookings to be consistent with 2025 results.
0 · Reply
StockNews_Live
StockNews_Live Mar. 2 at 1:33 PM
$QTRX Lucent Diagnostics, a brand of Quanterix Corporation, announced a partnership with Life Line Screening to offer non-invasive blood-based biomarker tests nationally. The partnership aims to expand acce…
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 26 at 4:20 PM
$QTRX Current Stock Price: $6.18 Contracts to trade: $5.0 QTRX Mar 20 2026 Call Entry: $1.00 Exit: $1.42 ROI: 42% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 25 at 3:34 PM
$QTRX RSI: 34.29, MACD: -0.2691 Vol: 0.33, MA20: 6.06, MA50: 6.57 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Feb. 23 at 4:37 PM
$QTRX huge block nearly 700k shares crossed @ 5.60 nearly 1.5% of total shares outstanding
0 · Reply
Rufusbird
Rufusbird Feb. 23 at 1:46 PM
$QTRX Alzheimer testing with blood tests on Mainstream Fox News this morning See: https://www.foxnews.com/health/blood-test-could-predict-when-alzheimers-symptoms-start-years-advance
0 · Reply
Rufusbird
Rufusbird Feb. 20 at 2:34 PM
$QTRX After riding through the down cycle, it is fun owning QTRX again! Let er run!
0 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Feb. 17 at 9:06 PM
$QTRX the merger consumed the bulk of 2025 from the time it was announced till now the shareprice was more than halved now its time to execute $10 sometime this calendar year isn't out of the question
0 · Reply
MaryMiceli912
MaryMiceli912 Feb. 11 at 2:35 PM
$QTRX Quanterix; life sciences tools (immunoassay); growth tied to biopharma R&D and academic funding; adoption of Simoa platform is key.
0 · Reply
ZacksResearch
ZacksResearch Feb. 4 at 6:13 PM
$QTRX just took a big regulatory step in Alzheimer’s testing. 🧠📄 Quanterix submitted a 510(k) to the FDA for its multi-analyte blood test designed to help evaluate cognitive symptoms for possible Alzheimer’s disease — a notable milestone in its diagnostic push. See why this filing matters and what comes next 👉 https://www.zacks.com/stock/news/2829232/quanterix-submits-fda-510k-for-multi-analyte-alzheimers-blood-test?cid=sm-stocktwits-2-2829232-teaser-32033&ADID=SYND_STOCKTWITS_TWEET_2_2829232_TEASER_32033
0 · Reply
ZacksResearch
ZacksResearch Feb. 4 at 5:13 PM
$QTRX drops after FDA submission news — why the market's missing the bigger picture! 🤔 Despite a 0.8% dip, QTRX's multi-analyte blood test for Alzheimer's could be a game-changer. The 510(k) submission, backed by extensive validation, positions Quanterix for growth in the Alzheimer’s market, valued at $7.72 billion in 2025 and projected to grow at a 9% CAGR through 2032. 📈 Discover the strategic impact here 👉 https://www.zacks.com/stock/news/2829232/quanterix-submits-fda-510k-for-multi-analyte-alzheimers-blood-test?cid=sm-stocktwits-2-2829232-body-32021&ADID=SYND_STOCKTWITS_TWEET_2_2829232_BODY_32021
0 · Reply
Rufusbird
Rufusbird Feb. 2 at 3:11 PM
$QTRX I sold all of my Niagen Bioscience shares and bought QTRS with the $
1 · Reply
IOMASS
IOMASS Jan. 27 at 7:11 PM
$QTRX Interesting trading volume today - down a bit with market but constructive...
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 24 at 12:22 AM
$QTRX Share Price: $6.49 Contract Selected: Aug 21, 2026 $10 Calls Buy Zone: $0.58 – $0.72 Target Zone: $1.06 – $1.29 Potential Upside: 72% ROI Time to Expiration: 209 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Swick02
Swick02 Jan. 23 at 6:56 PM
$QTRX price is back down to where it was before the new CEO announcement. We also learned that revenues and the cash position are both above forecast for year end. Adding more exposure here on this pullback.
0 · Reply
sakuzoh
sakuzoh Jan. 21 at 2:01 PM
$QTRX huge news https://www.stocktitan.net/news/QTRX/quanterix-announces-landmark-jama-study-highlighting-prognostic-sdqbd9t29qvi.html
0 · Reply
IOMASS
IOMASS Jan. 15 at 6:59 PM
$QTRX Don't need an activist at this stage as it appears QTRX is now positioned for growth/enhancing shareholder value but a smart guy entering the picture based on the new changes would help with credibility...
0 · Reply